Public Company Healthcare

Aptar Pharma

Crystal Lake, Illinois, United States

Global drug delivery dispensing systems and active material science solutions company providing drug product development and clinical trial materials manufacturing support for pharmaceutical customers, plus related digital health and patient engagement offerings.

Focus Areas
Drug delivery dispensing systems, Active material science, Drug formulation and development support
Website
aptar.com

Tracked deals

3

3 tracked deals across 2021-2026.

Recent pace

1

1 tracked deal announced in the last 12 months.

Deal mix

Buyout

2 buyout · 1 divestiture

Aptar Pharma Acquisition Volume by Year

Last 3 years

Acquisition volume by year Annual acquisition counts for the last 3 years for Aptar Pharma. 1 2021 1 2025 ~1 est. 1 2026
Actual Full-year estimate

Supporting Data

Recent Transactions

  • Aptar Pharma Acquires PULMOTREE
    October 30, 2026
    Buyer
    Aptar Pharma
    Target
    PULMOTREE
    Industry
    Medical Devices
    Location
    Bavaria, Germany
    Type
    Buyout

    Aptar Pharma acquired Munich-based PULMOTREE, adding its Kolibri non-propellant liquid inhaler technology to Aptar’s pulmonary drug-delivery portfolio. Aptar plans to integrate the platform with its formulation, device-engineering, regulatory, manufacturing, patient-onboarding, and digital-health capabilities to support pharmaceutical partners developing complex inhaled therapies.

  • Aptar Pharma Acquires Mod3 Pharma's Clinical Trial Materials Manufacturing Capabilities
    July 15, 2025
    Buyer
    Aptar Pharma (AptarGroup, Inc.)
    Target
    Mod3 Pharma (formerly Enteris Biopharma) - clinical trial materials manufacturing capabilities
    Seller
    SWK Holdings
    Industry
    Pharmaceuticals
    Location
    New Jersey, United States
    Type
    Divestiture

    Aptar Pharma has acquired the Phase 1 and 2 clinical trial materials manufacturing capabilities of Mod3 Pharma (formerly Enteris Biopharma) from SWK Holdings. The deal adds cGMP fill-and-finish, high-potency API suites and biologics capabilities at a Boonton, New Jersey facility to Aptar's drug delivery and early-stage development services to accelerate adoption of its delivery technologies.

  • AptarGroup Completes Acquisition of Majority Stake in Voluntis (Theraxium Digital Therapeutics)
    September 2, 2021
    Buyer
    AptarGroup, Inc.
    Target
    Voluntis
    Seller
    Voluntis's reference shareholders, Certain members of Voluntis' management, Bpifrance Participations, LBO France Gestion
    Industry
    Healthcare Services
    Location
    France
    Type
    Buyout

    AptarGroup, Inc. entered into exclusive negotiations and subsequently completed the acquisition of a majority stake (approximately 64.6%) in Voluntis, a digital therapeutics company. The transaction was followed by a mandatory cash tender offer to acquire Voluntis’ remaining shares at €8.70 per share, with a potential squeeze-out if regulatory conditions are met.

Related Acquisition Pages

Healthcare Services Buyers & Acquisitions 1 tracked deal by Aptar Pharma. Medical Devices Buyers & Acquisitions 1 tracked deal by Aptar Pharma. Pharmaceuticals Buyers & Acquisitions 1 tracked deal by Aptar Pharma. Acquisitions in New Jersey 1 tracked deal by Aptar Pharma.

Related articles

Selling a company? Get in front of buyers like Aptar Pharma

Turn tracked acquisition activity into an outreach-ready buyer list.

Find buyers like these →